Mirikizumab

Treatment for: Ulcerative Colitis U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab INDIANAPOLIS, April 13, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA […]
Read more